WM-8014: Selective KAT6A/B Inhibitor for Precision Epigenetic Research

Executive Summary: WM-8014 is a selective, reversible inhibitor of KAT6A (MOZ), KAT6B (MORF/QKF), KAT5, and KAT7 histone acetyltransferases, acting via competitive acetyl-CoA site binding (APExBIO, product page). It exhibits potent inhibition with IC₅₀ values of 8 nM (KAT6A) and 28 nM (KAT6B), confirmed in biochemical assays ([bioRxiv 2025](https://doi.org/10.1101/2025.09.17.676440)). WM-8014 induces cell cycle arrest and senescence through the p16INK4A–p19ARF pathway without inducing broad cytotoxicity in vitro. In vivo, it reduces liver overproliferation in a zebrafish KRAS G12V model, sparing normal tissue. High plasma protein binding limits its systemic use in mice; for in vivo murine studies, WM-1119 is recommended (APExBIO).

Biological Rationale

Histone acetyltransferases (HATs) such as KAT6A and KAT6B regulate gene expression by acetylating lysine residues on histones, influencing chromatin structure and transcriptional activity. Dysregulation of KAT6A/B activity is associated with cancer progression and resistance to therapy ([bioRxiv 2025](https://doi.org/10.1101/2025.09.17.676440)). Selective HAT inhibition provides a direct method to probe the role of epigenetic regulation in oncogene-induced senescence and cell cycle control. WM-8014 addresses the need for potent, selective, and reversible KAT6A/B inhibition in cancer biology and epigenetics research. Unlike pan-HAT inhibitors, WM-8014 offers high selectivity and minimal off-target cytotoxicity, making it suitable for dissecting pathway-specific effects in experimental settings (related review: This article provides updated in vivo data and focused mechanistic detail not covered in the review).

Mechanism of Action of WM-8014

WM-8014 is a competitive, reversible inhibitor that targets the acetyl-CoA binding site within the MYST domain of KAT6A, KAT6B, KAT5, and KAT7. The acyl sulfonyl hydrazide moiety of WM-8014 forms hydrogen bonds mimicking the diphosphate group of acetyl-CoA, leading to effective inhibition of acetyltransferase activity ([APExBIO](https://www.apexbt.com/wm-8014.html)). The compound exhibits the following IC₅₀ values under in vitro biochemical assay conditions (pH 7.4, 25°C, using recombinant enzyme):

• KAT6A: 8 nM
• KAT6B: 28 nM
• KAT5: 224 nM
• KAT7: 342 nM

This high degree of selectivity is essential for mechanistic studies, avoiding confounding effects from pan-acetyltransferase inhibition. WM-8014's competitive binding at the acetyl-CoA site was validated via X-ray crystallography and kinetic assays ([bioRxiv 2025, Fig 3b](https://doi.org/10.1101/2025.09.17.676440)). The compound does not induce apoptosis or general cytotoxicity at concentrations up to 10 μM in mouse embryonic fibroblasts (MEFs), as determined by RNA-seq and viability assays ([bioRxiv 2025](https://doi.org/10.1101/2025.09.17.676440)).

Evidence & Benchmarks

• WM-8014 inhibits KAT6A with an IC₅₀ of 8 nM (recombinant enzyme, pH 7.4, 25°C) (bioRxiv 2025).
• Selective inhibition of KAT6B (IC₅₀ = 28 nM), with >10-fold selectivity over KAT5 and KAT7 (IC₅₀ = 224 nM, 342 nM) (bioRxiv 2025).
• Induces cell cycle arrest and senescence in MEFs by upregulating Cdkn2a (p16INK4A/p19ARF) and downregulating Cdc6, without affecting global cell viability at ≤10 μM (bioRxiv 2025).
• In zebrafish models with KRAS G12V-driven hepatic overproliferation, WM-8014 treatment (0.5–2 μM, 48 h, 28°C) reduced liver volume and S phase entry, but did not impair normal liver growth (bioRxiv 2025).
• High aqueous solubility (8–16 μM) and excellent DMSO solubility (≥76.1 mg/mL) enable flexible laboratory workflows (APExBIO).
• Due to >99% plasma protein binding, in vivo efficacy in mice is limited; the derivative WM-1119 is preferred for murine studies (APExBIO).

Applications, Limits & Misconceptions

WM-8014 is widely used in cell cycle arrest assays, oncogene-induced senescence models, and epigenetic drug target validation studies. Its high selectivity enables robust mechanistic interrogation of the p16INK4A–p19ARF pathway in cancer biology research (related article: This article focuses on general selectivity, while our current text details kinetic and in vivo benchmarks). WM-8014 is not broadly cytotoxic, making it suitable for workflows where viability preservation is critical. However, its use is limited in systemic in vivo mouse models due to high plasma protein binding.

Common Pitfalls or Misconceptions

• WM-8014 is not suitable for long-term aqueous storage; solutions should be prepared fresh or stored at -20°C for short periods only.
• Not appropriate for pan-HAT inhibition studies; selectivity must be considered in experimental design.
• High plasma protein binding (>99%) precludes effective systemic use in murine models—use WM-1119 instead.
• Insoluble in ethanol or pure water; use DMSO as the preferred solvent for stock solutions.
• Does not induce apoptosis or cytotoxicity at recommended concentrations; it should not be used as a general cytotoxic agent.

For troubleshooting real-world applications, see the scenario-driven solutions in this workflow guide, which this article updates with more recent mechanistic and in vivo data.

Workflow Integration & Parameters

WM-8014 is supplied as a solid and can be dissolved in DMSO at ≥76.1 mg/mL for stock solutions. Working concentrations in cell-based assays typically range from 0.1 μM to 10 μM; higher concentrations are limited by aqueous solubility (8–16 μM) ([APExBIO](https://www.apexbt.com/wm-8014.html)). For in vitro enzyme assays, use buffer pH 7.4, 25°C, and pre-incubate enzyme with WM-8014 for 10–30 min before adding acetyl-CoA. In cell cycle or senescence studies, treat cells for 24–72 h and monitor gene expression (Cdkn2a, Cdc6) by qPCR or RNA-seq. Store the compound at -20°C and avoid repeated freeze-thaw cycles. For zebrafish studies, use 0.5–2 μM in embryo water at 28°C for 24–48 h to probe liver proliferation phenotypes.

For extended experimental workflows and best practices, refer to the detailed scenario-based recommendations in this protocol article, which our article expands upon with new selectivity and solubility data.

Conclusion & Outlook

WM-8014, as provided by APExBIO, is a highly selective KAT6A/B inhibitor that enables advanced, non-cytotoxic modulation of epigenetic pathways in cancer biology and drug target validation studies. Its robust benchmark data, precise selectivity, and compatibility with cell-based and zebrafish models make it a leading tool for dissecting oncogene-induced senescence and cell cycle arrest mechanisms. While its high plasma protein binding restricts use in systemic murine models, ongoing development of analogs such as WM-1119 addresses this limitation. WM-8014's performance parameters and mechanistic clarity position it at the forefront of precision epigenetic research.